{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:24:51Z","timestamp":1792070691179,"version":"4.4.0"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MR1-2022-12375880"],"award-info":[{"award-number":["PNRR-MR1-2022-12375880"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022FH7889"],"award-info":[{"award-number":["2022FH7889"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07796-w","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:36:59Z","timestamp":1770439019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research"],"prefix":"10.1186","volume":"24","author":[{"given":"Simona","family":"Granata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sorace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Stallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-6196","authenticated-orcid":false,"given":"Gianluigi","family":"Zaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"12","key":"7796_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nrneph.2011.149","volume":"7","author":"Y Liu","year":"2011","unstructured":"Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684\u201396.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"7796_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/ijms22010408","volume":"22","author":"S Panizo","year":"2021","unstructured":"Panizo S, Mart\u00ednez-Arias L, Alonso-Montes C, Cannata P, Mart\u00edn-Carro B, Fern\u00e1ndez-Mart\u00edn JL, Naves-D\u00edaz M. Carrillo-L\u00f3pez N, Cannata-And\u00eda JB. Fibrosis in chronic kidney disease: pathogenesis and consequences. Int J Mol Sci. 2021;22(1):408.","journal-title":"Int J Mol Sci"},{"issue":"10053","key":"7796_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and National life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459\u2013544.","journal-title":"Lancet"},{"issue":"10159","key":"7796_CR4","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, Pletcher MA, Smith AE, Tang K, Yuan CW, Brown JC, Friedman J, He J, Heuton KR, Holmberg M, Patel DJ, Reidy P, Carter A, Cercy K, Chapin A, Douwes-Schultz D, Frank T, Goettsch F, Liu PY, Nandakumar V, Reitsma MB, Reuter V, Sadat N, Sorensen RJD, Srinivasan V, Updike RL, York H, Lopez AD, Lozano R, Lim SS, Mokdad AH, Vollset SE, Murray CJL. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390.","journal-title":"Lancet"},{"issue":"9","key":"7796_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41581-022-00590-z","volume":"18","author":"L Li","year":"2022","unstructured":"Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol. 2022;18(9):545\u201357.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"7796_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1681\/ASN.2013080893","volume":"25","author":"D Zhou","year":"2014","unstructured":"Zhou D, Li Y, Zhou L, Tan RJ, Xiao L, Liang M, Hou FF, Liu Y. Sonic Hedgehog is a novel tubule-derived growth factor for interstitial fibroblasts after kidney injury. J Am Soc Nephrol. 2014;25(10):2187\u2013200.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"7796_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1681\/ASN.2008060566","volume":"20","author":"W He","year":"2009","unstructured":"He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt\/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009;20(4):765\u201376.","journal-title":"J Am Soc Nephrol"},{"key":"7796_CR8","doi-asserted-by":"publisher","first-page":"569322","DOI":"10.3389\/fphys.2020.569322","volume":"11","author":"L Sheng","year":"2020","unstructured":"Sheng L, Zhuang S. New insights into the role and mechanism of partial Epithelial-Mesenchymal transition in kidney fibrosis. Front Physiol. 2020;11:569322.","journal-title":"Front Physiol"},{"issue":"2","key":"7796_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrneph.2015.215","volume":"12","author":"D Zhou","year":"2016","unstructured":"Zhou D, Liu Y. Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol. 2016;12(2):68\u201370.","journal-title":"Nat Rev Nephrol"},{"key":"7796_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/1479-5876-11-292","volume":"11","author":"V Masola","year":"2013","unstructured":"Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A. Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med. 2013;11:292.","journal-title":"J Transl Med"},{"issue":"1","key":"7796_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12967-019-1770-1","volume":"17","author":"V Masola","year":"2019","unstructured":"Masola V, Carraro A, Granata S, Signorini L, Bellin G, Violi P, Lupo A, Tedeschi U, Onisto M, Gambaro G, Zaza G. In vitro effects of Interleukin (IL)-1 beta Inhibition on the epithelial-to-mesenchymal transition (EMT) of renal tubular and hepatic stellate cells. J Transl Med. 2019;17(1):12.","journal-title":"J Transl Med"},{"key":"7796_CR12","doi-asserted-by":"publisher","first-page":"601325","DOI":"10.3389\/fphar.2020.601325","volume":"11","author":"J Xu","year":"2020","unstructured":"Xu J, Zhou L, Liu Y. Cellular senescence in kidney fibrosis: pathologic significance and therapeutic strategies. Front Pharmacol. 2020;11:601325.","journal-title":"Front Pharmacol"},{"issue":"3","key":"7796_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MNH.0000000000000782","volume":"31","author":"H Tan","year":"2022","unstructured":"Tan H, Xu J, Liu Y. Ageing, cellular senescence and chronic kidney disease: experimental evidence. Curr Opin Nephrol Hypertens. 2022;31(3):235\u201343.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"7796_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/ndt\/gfad257","volume":"39","author":"M He","year":"2024","unstructured":"He M, Liu Z, Li L, Liu Y. Cell-cell communication in kidney fibrosis. Nephrol Dial Transpl. 2024;39(5):761\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"7796_CR15","doi-asserted-by":"publisher","first-page":"103466","DOI":"10.1016\/j.autrev.2023.103466","volume":"23","author":"D Roccatello","year":"2024","unstructured":"Roccatello D, Lan HY, Sciascia S, Sethi S, Fornoni A, Glassock R. From inflammation to renal fibrosis: A one-way road in autoimmunity? Autoimmun Rev. 2024;23(4):103466.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"7796_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nm.3218","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu VS, Taduri G, O\u2019Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19(8):1047\u201353.","journal-title":"Nat Med"},{"issue":"5","key":"7796_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41581-025-00934-5","volume":"21","author":"L Abbad","year":"2025","unstructured":"Abbad L, Esteve E, Chatziantoniou C. Advances and challenges in kidney fibrosis therapeutics. Nat Rev Nephrol. 2025;21(5):314\u201329.","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"7796_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41581-023-00752-7","volume":"19","author":"S Tanaka","year":"2023","unstructured":"Tanaka S, Portilla D, Okusa MD. Role of perivascular cells in kidney homeostasis, inflammation, repair and fibrosis. Nat Rev Nephrol. 2023;19(11):721\u201332.","journal-title":"Nat Rev Nephrol"},{"issue":"7841","key":"7796_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","volume":"589","author":"C Kuppe","year":"2021","unstructured":"Kuppe C, Ibrahim MM, Kranz J, Zhang X, Ziegler S, Perales-Pat\u00f3n J, Jansen J, Reimer KC, Smith JR, Dobie R, Wilson-Kanamori JR, Halder M, Xu Y, Kabgani N, Kaesler N, Klaus M, Gernhold L, Puelles VG, Huber TB, Boor P, Menzel S, Hoogenboezem RM, Bindels EMJ, Steffens J, Floege J, Schneider RK, Saez-Rodriguez J, Henderson NC, Kramann R. Decoding myofibroblast origins in human kidney fibrosis. Nature. 2021;589(7841):281\u20136.","journal-title":"Nature"},{"issue":"1","key":"7796_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41467-024-44886-z","volume":"15","author":"C Cohen","year":"2024","unstructured":"Cohen C, Mhaidly R, Croizer H, Kieffer Y, Leclere R, Vincent-Salomon A, Robley C, Anglicheau D, Rabant M, Sannier A, Timsit MO, Eddy S, Kretzler M, Ju W, Mechta-Grigoriou F. WNT-dependent interaction between inflammatory fibroblasts and FOLR2\u2009+\u2009macrophages promotes fibrosis in chronic kidney disease. Nat Commun. 2024;15(1):743.","journal-title":"Nat Commun"},{"issue":"12","key":"7796_CR21","doi-asserted-by":"publisher","first-page":"e2495","DOI":"10.1038\/cddis.2016.402","volume":"7","author":"XM Meng","year":"2016","unstructured":"Meng XM, Wang S, Huang XR, Yang C, Xiao J, Zhang Y, To KF, Nikolic-Paterson DJ, Lan HY. Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis. Cell Death Dis. 2016;7(12):e2495.","journal-title":"Cell Death Dis"},{"issue":"4","key":"7796_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.semnephrol.2014.06.004","volume":"34","author":"R Kramann","year":"2014","unstructured":"Kramann R, Humphreys BD. Kidney pericytes: roles in regeneration and fibrosis. Semin Nephrol. 2014;34(4):374\u201383.","journal-title":"Semin Nephrol"},{"issue":"4","key":"7796_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000365149","volume":"51","author":"C Schrimpf","year":"2014","unstructured":"Schrimpf C, Teebken OE, Wilhelmi M, Duffield JS. The role of pericyte detachment in vascular rarefaction. J Vasc Res. 2014;51(4):247\u201358.","journal-title":"J Vasc Res"},{"issue":"1","key":"7796_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajpath.2012.09.009","volume":"182","author":"CF Wu","year":"2013","unstructured":"Wu CF, Chiang WC, Lai CF, Chang FC, Chen YT, Chou YH, Wu TH, Linn GR, Ling H, Wu KD, Tsai TJ, Chen YM, Duffield JS, Lin SL. Transforming growth factor \u03b2-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol. 2013;182(1):118\u201331.","journal-title":"Am J Pathol"},{"issue":"11","key":"7796_CR25","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ki.2011.208","volume":"80","author":"YT Chen","year":"2011","unstructured":"Chen YT, Chang FC, Wu CF, Chou YH, Hsu HL, Chiang WC, Shen J, Chen YM, Wu KD, Tsai TJ, Duffield JS, Lin SL. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int. 2011;80(11):1170\u201381.","journal-title":"Kidney Int"},{"issue":"1","key":"7796_CR26","doi-asserted-by":"publisher","first-page":"16914","DOI":"10.1038\/s41598-017-17193-5","volume":"7","author":"N Wang","year":"2017","unstructured":"Wang N, Deng Y, Liu A, Shen N, Wang W, Du X, Tang Q, Li S, Odeh Z, Wu T, Lin H. Novel mechanism of the Pericyte-Myofibroblast transition in renal interstitial fibrosis: core fucosylation regulation. Sci Rep. 2017;7(1):16914.","journal-title":"Sci Rep"},{"issue":"3","key":"7796_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41581-020-00343-w","volume":"17","author":"SJ Schunk","year":"2021","unstructured":"Schunk SJ, Floege J, Fliser D, Speer T. WNT-\u03b2-catenin signalling - a versatile player in kidney injury and repair. Nat Rev Nephrol. 2021;17(3):172\u201384.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"7796_CR28","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1681\/ASN.2009010019","volume":"20","author":"C Dai","year":"2009","unstructured":"Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt\/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol. 2009;20(9):1997\u20132008.","journal-title":"J Am Soc Nephrol"},{"issue":"35","key":"7796_CR29","doi-asserted-by":"crossref","first-page":"re9","DOI":"10.1126\/scisignal.135re9","volume":"1","author":"R van Amerongen","year":"2008","unstructured":"van Amerongen R, Mikels A, Nusse R. Alternative Wnt signaling is initiated by distinct receptors. Sci Signal. 2008;1(35):re9.","journal-title":"Sci Signal"},{"issue":"12","key":"7796_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1134\/S0006297910120023","volume":"75","author":"VL Katanaev","year":"2010","unstructured":"Katanaev VL. The Wnt\/Frizzled GPCR signaling pathway. Biochem (Mosc). 2010;75(12):1428\u201334.","journal-title":"Biochem (Mosc)"},{"key":"7796_CR31","doi-asserted-by":"publisher","first-page":"1517181","DOI":"10.3389\/fcell.2024.1517181","volume":"12","author":"Y Chen","year":"2025","unstructured":"Chen Y, Xue C. Cross-talk of renal cells through WNT signal transduction in the development of fibrotic kidneys. Front Cell Dev Biol. 2025;12:1517181.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"7796_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1681\/ASN.2017040391","volume":"29","author":"Y Feng","year":"2018","unstructured":"Feng Y, Ren J, Gui Y, Wei W, Shu B, Lu Q, Xue X, Sun X, He W, Yang J, Dai C. Wnt\/\u03b2-Catenin-Promoted macrophage alternative activation contributes to kidney fibrosis. J Am Soc Nephrol. 2018;29(1):182\u201393.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"7796_CR33","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1681\/ASN.2017050574","volume":"29","author":"C Luo","year":"2018","unstructured":"Luo C, Zhou S, Zhou Z, Liu Y, Yang L, Liu J, Zhang Y, Li H, Liu Y, Hou FF, Zhou L. Wnt9a promotes renal fibrosis by accelerating cellular senescence in tubular epithelial cells. J Am Soc Nephrol. 2018;29(4):1238\u201356.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"7796_CR34","doi-asserted-by":"publisher","first-page":"e13004","DOI":"10.1111\/acel.13004","volume":"18","author":"J Miao","year":"2019","unstructured":"Miao J, Liu J, Niu J, Zhang Y, Shen W, Luo C, Liu Y, Li C, Li H, Yang P, Liu Y, Hou FF, Zhou L. Wnt\/\u03b2-catenin\/RAS signaling mediates age-related renal fibrosis and is associated with mitochondrial dysfunction. Aging Cell. 2019;18(5):e13004.","journal-title":"Aging Cell"},{"issue":"5","key":"7796_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/ki.2012.173","volume":"82","author":"D Zhou","year":"2012","unstructured":"Zhou D, Li Y, Lin L, Zhou L, Igarashi P, Liu Y. Tubule-specific ablation of endogenous \u03b2-catenin aggravates acute kidney injury in mice. Kidney Int. 2012;82(5):537\u201347.","journal-title":"Kidney Int"},{"issue":"9","key":"7796_CR36","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1681\/ASN.2009030253","volume":"20","author":"Z Wang","year":"2009","unstructured":"Wang Z, Havasi A, Gall JM, Mao H, Schwartz JH, Borkan SC. Beta-catenin promotes survival of renal epithelial cells by inhibiting Bax. J Am Soc Nephrol. 2009;20(9):1919\u201328.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"7796_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ki.2012.239","volume":"82","author":"C Howard","year":"2012","unstructured":"Howard C, Tao S, Yang HC, Fogo AB, Woodgett JR, Harris RC, Rao R. Specific deletion of glycogen synthase kinase-3\u03b2 in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney Int. 2012;82(9):1000\u20139.","journal-title":"Kidney Int"},{"issue":"9","key":"7796_CR38","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.0912228107","volume":"107","author":"SL Lin","year":"2010","unstructured":"Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT, Pei H, Chen L, Zheng JJ, Carroll TJ, Pollard JW, McMahon AP, Lang RA, Duffield JS. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci U S A. 2010;107(9):4194\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"7796_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1681\/ASN.2016121362","volume":"29","author":"X Qiao","year":"2018","unstructured":"Qiao X, Rao P, Zhang Y, Liu L, Pang M, Wang H, Hu M, Tian X, Zhang J, Zhao Y, Wang XM, Wang C, Yu H, Guo F, Cao Q, Wang Y, Wang YM, Zhang GY, Lee VW, Alexander SI, Zheng G, Harris DCH. Redirecting TGF-\u03b2 signaling through the \u03b2-Catenin\/Foxo complex prevents kidney fibrosis. J Am Soc Nephrol. 2018;29(2):557\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"7796_CR40","doi-asserted-by":"crossref","unstructured":"Rao P, Pang M, Qiao X, Yu H, Wang H, Yang Y, Ren X, Hu M, Chen T, Cao Q, Wang Y, Khushi M, Zhang G, Wang YM, Heok P\u2019ng C, Nankivell B, Lee VW, Alexander SI, Zheng G, Harris DC. Promotion of \u03b2-catenin\/Foxo1 signaling ameliorates renal interstitial fibrosis. Lab Invest. 2019;99(11):1689\u20131701.","DOI":"10.1038\/s41374-019-0276-z"},{"issue":"10","key":"7796_CR41","doi-asserted-by":"publisher","first-page":"e135454","DOI":"10.1172\/jci.insight.135454","volume":"5","author":"S Nlandu-Khodo","year":"2020","unstructured":"Nlandu-Khodo S, Osaki Y, Scarfe L, Yang H, Phillips-Mignemi M, Tonello J, Saito-Diaz K, Neelisetty S, Ivanova A, Huffstater T, McMahon R, Taketo MM, deCaestecker M, Kasinath B, Harris RC, Lee E, Gewin LS. Tubular \u03b2-catenin and FoxO3 interactions protect in chronic kidney disease. JCI Insight. 2020;5(10):e135454.","journal-title":"JCI Insight"},{"key":"7796_CR42","doi-asserted-by":"crossref","unstructured":"Maiese K, Hou J, Chong ZZ, Shang YC. A fork in the path: developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev. 2009 Jul-Aug;2(3):119\u201329.","DOI":"10.4161\/oxim.2.3.8916"},{"key":"7796_CR43","doi-asserted-by":"publisher","first-page":"719880","DOI":"10.3389\/fphar.2021.719880","volume":"12","author":"SS Li","year":"2021","unstructured":"Li SS, Sun Q, Hua MR, Suo P, Chen JR, Yu XY, Zhao YY. Targeting the Wnt\/\u03b2-Catenin signaling pathway as a potential therapeutic strategy in renal tubulointerstitial fibrosis. Front Pharmacol. 2021;12:719880.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7796_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cellsig.2013.09.016","volume":"26","author":"CP Xavier","year":"2014","unstructured":"Xavier CP, Melikova M, Chuman Y, \u00dcren A, Baljinnyam B, Rubin JS. Secreted Frizzled-related protein potentiation versus Inhibition of Wnt3a\/\u03b2-catenin signaling. Cell Signal. 2014;26(1):94\u2013101.","journal-title":"Cell Signal"},{"issue":"11","key":"7796_CR45","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/ki.2011.255","volume":"80","author":"D Wang","year":"2011","unstructured":"Wang D, Dai C, Li Y, Liu Y. Canonical Wnt\/\u03b2-catenin signaling mediates transforming growth factor-\u03b21-driven podocyte injury and proteinuria. Kidney Int. 2011;80(11):1159\u201369.","journal-title":"Kidney Int"},{"issue":"32","key":"7796_CR46","doi-asserted-by":"publisher","first-page":"23368","DOI":"10.1074\/jbc.M113.460394","volume":"288","author":"L Jiang","year":"2013","unstructured":"Jiang L, Xu L, Song Y, Li J, Mao J, Zhao AZ, He W, Yang J, Dai C. Calmodulin-dependent protein kinase II\/cAMP response element-binding protein\/Wnt\/\u03b2-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria. J Biol Chem. 2013;288(32):23368\u201379.","journal-title":"J Biol Chem"},{"issue":"1","key":"7796_CR47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1681\/ASN.2008101059","volume":"21","author":"CL Lin","year":"2010","unstructured":"Lin CL, Wang JY, Ko JY, Huang YT, Kuo YH, Wang FS. Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J Am Soc Nephrol. 2010;21(1):124\u201335.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"7796_CR48","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1681\/ASN.2013080818","volume":"25","author":"Y Fang","year":"2014","unstructured":"Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA. CKD-induced wingless\/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol. 2014;25(8):1760\u201373.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"7796_CR49","doi-asserted-by":"publisher","first-page":"7679","DOI":"10.3390\/ijms24087679","volume":"24","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Chang CC, Hsieh CC, Huang YT, Shih YH, Chang HC, Chang PJ, Lin CL. Dickkopf-1 acts as a profibrotic mediator in progressive chronic kidney disease. Int J Mol Sci. 2023;24(8):7679.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7796_CR50","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1681\/ASN.2012080865","volume":"24","author":"L Zhou","year":"2013","unstructured":"Zhou L, Li Y, Zhou D, Tan RJ, Liu Y. Loss of Klotho contributes to kidney injury by derepression of Wnt\/\u03b2-catenin signaling. J Am Soc Nephrol. 2013;24(5):771\u201385.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"7796_CR51","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/path.4420","volume":"234","author":"X Guan","year":"2014","unstructured":"Guan X, Nie L, He T, Yang K, Xiao T, Wang S, Huang Y, Zhang J, Wang J, Sharma K, Liu Y, Zhao J. Klotho suppresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2 signalling. J Pathol. 2014;234(4):560\u201372.","journal-title":"J Pathol"},{"issue":"2","key":"7796_CR52","doi-asserted-by":"publisher","first-page":"e14696","DOI":"10.14814\/phy2.14696","volume":"9","author":"J Miao","year":"2021","unstructured":"Miao J, Huang J, Luo C, Ye H, Ling X, Wu Q, Shen W, Zhou L. Klotho retards renal fibrosis through targeting mitochondrial dysfunction and cellular senescence in renal tubular cells. Physiol Rep. 2021;9(2):e14696.","journal-title":"Physiol Rep"},{"issue":"1","key":"7796_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13578-024-01226-4","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Wang H, Liu Q, Long S, Wu Y, Wang N, Lin W, Chen G, Lin M, Wen J. Klotho exerts protection in chronic kidney disease associated with regulating inflammatory response and lipid metabolism. Cell Biosci. 2024;14(1):46.","journal-title":"Cell Biosci"},{"key":"7796_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.addr.2017.07.009","volume":"121","author":"R Mencke","year":"2017","unstructured":"Mencke R, Olauson H, Hillebrands JL. Effects of Klotho on fibrosis and cancer: A renal focus on mechanisms and therapeutic strategies. Adv Drug Deliv Rev. 2017;121:85\u2013100.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"7796_CR55","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41467-022-28096-z","volume":"13","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Ren Q, Li L, Tan H, Lu M, Tian Y, Huang L, Zhao B, Fu H, Hou FF, Zhou L, Liu Y. A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-\u03b2 signaling. Nat Commun. 2022;13(1):438.","journal-title":"Nat Commun"},{"issue":"45","key":"7796_CR56","doi-asserted-by":"publisher","first-page":"31526","DOI":"10.1074\/jbc.M114.584565","volume":"289","author":"M Matsuyama","year":"2014","unstructured":"Matsuyama M, Nomori A, Nakakuni K, Shimono A, Fukushima M. Secreted Frizzled-related protein 1 (Sfrp1) regulates the progression of renal fibrosis in a mouse model of obstructive nephropathy. J Biol Chem. 2014;289(45):31526\u201333.","journal-title":"J Biol Chem"},{"issue":"1","key":"7796_CR57","doi-asserted-by":"publisher","first-page":"20240934","DOI":"10.1515\/med-2024-0934","volume":"19","author":"D Deng","year":"2024","unstructured":"Deng D, Tian D, Wang Y, Bai Y, Diao Z, Liu W. Secreted frizzled-related protein 5 protects against renal fibrosis by inhibiting Wnt\/\u03b2-catenin pathway. Open Med (Wars). 2024;19(1):20240934.","journal-title":"Open Med (Wars)"},{"issue":"12","key":"7796_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1042\/CS20120517","volume":"124","author":"C Fang","year":"2013","unstructured":"Fang C, Shen L, Dong L, Liu M, Shi S, Dong N, Wu Q. Reduced urinary Corin levels in patients with chronic kidney disease. Clin Sci (Lond). 2013;124(12):709\u201317.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"7796_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ajpath.2023.09.008","volume":"194","author":"X Su","year":"2024","unstructured":"Su X, Li S, Zhang Y, Tie X, Feng R, Guo X, Qiao X, Wang L. Overexpression of Corin ameliorates kidney fibrosis through Inhibition of Wnt\/\u03b2-Catenin signaling in mice. Am J Pathol. 2024;194(1):101\u201320.","journal-title":"Am J Pathol"},{"issue":"1","key":"7796_CR60","doi-asserted-by":"publisher","first-page":"166874","DOI":"10.1016\/j.bbadis.2023.166874","volume":"1870","author":"C Lee","year":"2024","unstructured":"Lee C, Pratap K, Zhang L, Chen HD, Gautam S, Arnaoutova I, Raghavankutty M, Starost MF, Kahn M, Mansfield BC, Chou JY. Inhibition of Wnt\/\u03b2-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia. Biochim Biophys Acta Mol Basis Dis. 2024;1870(1):166874.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"9","key":"7796_CR61","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1681\/ASN.2010101079","volume":"22","author":"S Hao","year":"2011","unstructured":"Hao S, He W, Li Y, Ding H, Hou Y, Nie J, Hou FF, Kahn M, Liu Y. Targeted Inhibition of \u03b2-catenin\/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol. 2011;22(9):1642\u201353.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"7796_CR62","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/14728222.2021.1992386","volume":"25","author":"M Kahn","year":"2021","unstructured":"Kahn M. Taking the road less traveled - the therapeutic potential of CBP\/\u03b2-catenin antagonists. Expert Opin Ther Targets. 2021;25(9):701\u201319.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"7796_CR63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1681\/ASN.2014010085","volume":"26","author":"L Zhou","year":"2015","unstructured":"Zhou L, Li Y, Hao S, Zhou D, Tan RJ, Nie J, Hou FF, Kahn M, Liu Y. Multiple genes of the renin-angiotensin system are novel targets of Wnt\/\u03b2-catenin signaling. J Am Soc Nephrol. 2015;26(1):107\u201320.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"7796_CR64","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3892\/mmr.2017.6461","volume":"15","author":"X Lin","year":"2017","unstructured":"Lin X, Zha Y, Zeng XZ, Dong R, Wang QH, Wang DT. Role of the Wnt\/\u03b2-catenin signaling pathway in inducing apoptosis and renal fibrosis in 5\/6-nephrectomized rats. Mol Med Rep. 2017;15(6):3575\u201382.","journal-title":"Mol Med Rep"},{"issue":"6","key":"7796_CR65","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.bbadis.2019.01.027","volume":"1865","author":"L Xiao","year":"2019","unstructured":"Xiao L, Xu B, Zhou L, Tan RJ, Zhou D, Fu H, Li A, Hou FF, Liu Y. Wnt\/\u03b2-catenin regulates blood pressure and kidney injury in rats. Biochim Biophys Acta Mol Basis Dis. 2019;1865(6):1313\u201322.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"34","key":"7796_CR66","doi-asserted-by":"publisher","first-page":"12682","DOI":"10.1073\/pnas.0404875101","volume":"101","author":"KH Emami","year":"2004","unstructured":"Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR, Kahn M. A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription. Proc Natl Acad Sci U S A. 2004;101(34):12682\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7796_CR67","doi-asserted-by":"publisher","first-page":"108917","DOI":"10.1016\/j.biopha.2019.108917","volume":"115","author":"X Yang","year":"2019","unstructured":"Yang X, Thorngren D, Chen Q, Wang M, Xie X. Protective role of relaxin in a mouse model of aristolochic acid nephropathy. Biomed Pharmacother. 2019;115:108917.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"7796_CR68","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1046\/j.1523-1755.2001.059003876.x","volume":"59","author":"SL Garber","year":"2001","unstructured":"Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001;59(3):876\u201382.","journal-title":"Kidney Int"},{"issue":"1","key":"7796_CR69","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/0886022X.2022.2044351","volume":"44","author":"C Feiteng","year":"2022","unstructured":"Feiteng C, Lei C, Deng L, Chaoliang X, Zijie X, Yi S, Minglei S. Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt\/\u03b2-catenin signaling pathway. Ren Fail. 2022;44(1):513\u201324.","journal-title":"Ren Fail"},{"key":"7796_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mce.2018.12.017","volume":"487","author":"AL Valkovic","year":"2019","unstructured":"Valkovic AL, Bathgate RA, Samuel CS, Kocan M. Understanding relaxin signalling at the cellular level. Mol Cell Endocrinol. 2019;487:24\u201333.","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"7796_CR71","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.7150\/ijbs.101548","volume":"21","author":"Q Hong","year":"2025","unstructured":"Hong Q, Kim H, Cai GY, Chen XM, He JC, Lee K. Modulation of TGF-\u03b2 signaling new approaches toward kidney disease and fibrosis therapy. Int J Biol Sci. 2025;21(4):1649\u201365.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"7796_CR72","doi-asserted-by":"publisher","first-page":"e23529","DOI":"10.1002\/dvg.23529","volume":"62","author":"S Hadpech","year":"2024","unstructured":"Hadpech S, Thongboonkerd V. Epithelial-mesenchymal plasticity in kidney fibrosis. Genesis. 2024;62(1):e23529.","journal-title":"Genesis"},{"issue":"10","key":"7796_CR73","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1097\/01.ASN.0000033611.79556.AE","volume":"13","author":"EP B\u00f6ttinger","year":"2002","unstructured":"B\u00f6ttinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13(10):2600\u201310.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"7796_CR74","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/nm888","volume":"9","author":"M Zeisberg","year":"2003","unstructured":"Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9(7):964\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"7796_CR75","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3892\/mmr.2017.7025","volume":"16","author":"Y Wang","year":"2017","unstructured":"Wang Y, Xiao Y, Li S, Shi L, Liu L, Zhang Y, Shi M, Guo B. BMP-7 enhances SnoN mRNA expression in renal tubular epithelial cells under high-glucose conditions. Mol Med Rep. 2017;16(3):3308\u201314.","journal-title":"Mol Med Rep"},{"issue":"1","key":"7796_CR76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/path.4430","volume":"235","author":"X Peng","year":"2015","unstructured":"Peng X, Xiao Z, Zhang J, Li Y, Dong Y, Du J. IL-17A produced by both \u03b3\u03b4 T and Th17 cells promotes renal fibrosis via RANTES-mediated leukocyte infiltration after renal obstruction. J Pathol. 2015;235(1):79\u201389.","journal-title":"J Pathol"},{"key":"7796_CR77","doi-asserted-by":"publisher","first-page":"116957","DOI":"10.1016\/j.lfs.2019.116957","volume":"238","author":"L Liu","year":"2019","unstructured":"Liu L, Wang Y, Yan R, Liang L, Zhou X, Liu H, Zhang X, Mao Y, Peng W, Xiao Y, Zhang F, Liu L, Shi M, Guo B. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation. Life Sci. 2019;238:116957.","journal-title":"Life Sci"},{"issue":"12","key":"7796_CR78","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1016\/j.bbadis.2017.09.011","volume":"1863","author":"DF Higgins","year":"2017","unstructured":"Higgins DF, Ewart LM, Masterson E, Tennant S, Grebnev G, Prunotto M, Pomposiello S, Conde-Knape K, Martin FM, Godson C. BMP7-induced-Pten inhibits Akt and prevents renal fibrosis. Biochim Biophys Acta Mol Basis Dis. 2017;1863(12):3095\u2013104.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"12","key":"7796_CR79","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/ph15121485","volume":"15","author":"CH Park","year":"2022","unstructured":"Park CH, Yoo TH. TGF-\u03b2 inhibitors for therapeutic management of kidney fibrosis. Pharmaceuticals (Basel). 2022;15(12):1485.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7796_CR80","doi-asserted-by":"publisher","first-page":"105910","DOI":"10.1016\/j.phrs.2021.105910","volume":"173","author":"T Xue","year":"2021","unstructured":"Xue T, Qiu X, Liu H, Gan C, Tan Z, Xie Y, Wang Y, Ye T. Epigenetic regulation in fibrosis progress. Pharmacol Res. 2021;173:105910.","journal-title":"Pharmacol Res"},{"issue":"2","key":"7796_CR81","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ymthe.2023.12.009","volume":"32","author":"YY Gu","year":"2024","unstructured":"Gu YY, Liu XS, Lan HY. Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs. Mol Ther. 2024;32(2):313\u201324.","journal-title":"Mol Ther"},{"issue":"11","key":"7796_CR82","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ki.2011.33","volume":"79","author":"H Trachtman","year":"2011","unstructured":"Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. A phase 1, single-dose study of fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011;79(11):1236\u201343.","journal-title":"Kidney Int"},{"issue":"5","key":"7796_CR83","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","volume":"2","author":"F Vincenti","year":"2017","unstructured":"Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J. Focal segmental glomerulosclerosis study Group. A phase 2, Double-Blind, Placebo-Controlled, randomized study of fresolimumab in patients with Steroid-Resistant primary focal segmental glomerulosclerosis. Kidney Int Rep. 2017;2(5):800\u201310.","journal-title":"Kidney Int Rep"},{"issue":"12","key":"7796_CR84","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00424-024-03029-5","volume":"476","author":"S Schwalm","year":"2024","unstructured":"Schwalm S, Manaila R, Oftring A, Schaefer L, von Gunten S, Pfeilschifter J. The contribution of 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives. Pflugers Arch. 2024;476(12):1845\u201361.","journal-title":"Pflugers Arch"},{"issue":"8","key":"7796_CR85","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/ki.2012.224","volume":"82","author":"SW Park","year":"2012","unstructured":"Park SW, Kim M, Kim JY, Brown KM, Haase VH, D\u2019Agati VD, Lee HT. Proximal tubule sphingosine kinase-1 has a critical role in A1 adenosine receptor-mediated renal protection from ischemia. Kidney Int. 2012;82(8):878\u201391.","journal-title":"Kidney Int"},{"issue":"2","key":"7796_CR86","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.2008.400","volume":"75","author":"SK Jo","year":"2009","unstructured":"Jo SK, Bajwa A, Ye H, Vergis AL, Awad AS, Kharel Y, Lynch KR, Okusa MD. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int. 2009;75(2):167\u201375.","journal-title":"Kidney Int"},{"key":"7796_CR87","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1681\/ASN.2016030306","volume":"28","author":"A Bajwa","year":"2017","unstructured":"Bajwa A, Huang L, Kurmaeva E, Ye H, Dondeti KR, Chroscicki P, Foley LS, Balogun ZA, Alexander KJ, Park H. Sphingosine kinase 2 deficiency attenuates kidney fibrosis via IFN-\u03b3. J Am Soc Nephrol. 2017;28:1145.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"7796_CR88","doi-asserted-by":"publisher","first-page":"e0194053","DOI":"10.1371\/journal.pone.0194053","volume":"13","author":"M Ghosh","year":"2018","unstructured":"Ghosh M, Thangada S, Dasgupta O, Khanna KM, Yamase HT, Kashgarian M, Hla T, Shapiro LH, Ferrer FA. Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. PLoS ONE. 2018;13(3):e0194053.","journal-title":"PLoS ONE"},{"issue":"11","key":"7796_CR89","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.ajpath.2017.06.017","volume":"187","author":"S Schwalm","year":"2017","unstructured":"Schwalm S, Beyer S, Frey H, Haceni R, Grammatikos G, Thomas D, Geisslinger G, Schaefer L, Huwiler A, Pfeilschifter J. Sphingosine Kinase-2 deficiency ameliorates kidney fibrosis by Up-Regulating Smad7 in a mouse model of unilateral ureteral obstruction. Am J Pathol. 2017;187(11):2413\u201329.","journal-title":"Am J Pathol"},{"issue":"11","key":"7796_CR90","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1016\/j.bbadis.2018.09.007","volume":"1864","author":"X Zhu","year":"2018","unstructured":"Zhu X, Shi D, Cao K, Ru D, Ren J, Rao Z, Chen Y, You Q, Dai C, Liu L, Zhou H. Sphingosine kinase 2 cooperating with Fyn promotes kidney fibroblast activation and fibrosis via STAT3 and AKT. Biochim Biophys Acta Mol Basis Dis. 2018;1864(11):3824\u201336.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"7796_CR91","doi-asserted-by":"publisher","first-page":"104170","DOI":"10.1016\/j.phrs.2019.02.009","volume":"154","author":"B Stepanovska","year":"2020","unstructured":"Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacol Res. 2020;154:104170.","journal-title":"Pharmacol Res"},{"key":"7796_CR92","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","volume":"185","author":"A Huwiler","year":"2018","unstructured":"Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator Fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther. 2018;185:34\u201349.","journal-title":"Pharmacol Ther"},{"issue":"5 Suppl","key":"7796_CR93","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.juro.2013.10.072","volume":"191","author":"S Thangada","year":"2014","unstructured":"Thangada S, Shapiro LH, Silva C, Yamase H, Hla T, Ferrer FA. Treatment with the Immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction. J Urol. 2014;191(5 Suppl):1508\u201316.","journal-title":"J Urol"},{"issue":"1","key":"7796_CR94","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cei.13003","volume":"190","author":"T Tian","year":"2017","unstructured":"Tian T, Zhang J, Zhu X, Wen S, Shi D, Zhou H. FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-\u03b2 signalling in fibroblasts. Clin Exp Immunol. 2017;190(1):68\u201378.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"7796_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502855","volume":"51","author":"X Li","year":"2020","unstructured":"Li X, Wu M, Chen L, Lu J, Li G, Fu L, Qi N, Lin Y, Sun Z, Wang X, Zhang H, Liu J, Jiang H, Li L, Mei CL, Luo C. A Sphingosine-1-Phosphate modulator ameliorates polycystic kidney disease in han:sprd rats. Am J Nephrol. 2020;51(1):1\u201310.","journal-title":"Am J Nephrol"},{"issue":"12","key":"7796_CR96","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","volume":"6","author":"M Salvadori","year":"2006","unstructured":"Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, Eris J, Schena FP, Eisenberger U, Rostaing L, Hmissi A, Aradhye S, FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de Novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transpl. 2006;6(12):2912\u201321.","journal-title":"Am J Transpl"},{"issue":"12","key":"7796_CR97","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/01.tp.0000251718.95622.b3","volume":"82","author":"H Tedesco-Silva","year":"2006","unstructured":"Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, Gugliuzza KK, Rajagopalan PR, Esmeraldo Rde M, Lord H, Salvadori M, Slade JM, FTY720 Study Group. Randomized controlled trial of FTY720 versus MMF in de Novo renal transplantation. Transplantation. 2006;82(12):1689\u201397.","journal-title":"Transplantation"},{"issue":"7","key":"7796_CR98","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/01.tp.0000281385.26500.3b","volume":"84","author":"H Tedesco-Silva","year":"2007","unstructured":"Tedesco-Silva H, Szakaly P, Shoker A, Sommerer C, Yoshimura N, Schena FP, Cremer M, Hmissi A, Mayer H, Lang P, FTY720 2218 Clinical Study Group. FTY720 versus mycophenolate mofetil in de Novo renal transplantation: six-month results of a double-blind study. Transplantation. 2007;84(7):885\u201392.","journal-title":"Transplantation"},{"key":"7796_CR99","doi-asserted-by":"publisher","first-page":"109881","DOI":"10.1016\/j.cellsig.2020.109881","volume":"79","author":"S Schwalm","year":"2021","unstructured":"Schwalm S, Beyer S, Hafizi R, Trautmann S, Geisslinger G, Adams DR, Pyne S, Pyne N, Schaefer L, Huwiler A, Pfeilschifter J. Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cell Signal. 2021;79:109881.","journal-title":"Cell Signal"},{"issue":"5","key":"7796_CR100","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/emboj.2009.12","volume":"28","author":"J Briscoe","year":"2009","unstructured":"Briscoe J. Making a grade: Sonic Hedgehog signalling and the control of neural cell fate. EMBO J. 2009;28(5):457\u201365.","journal-title":"EMBO J"},{"issue":"5","key":"7796_CR101","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1681\/ASN.2011060614","volume":"23","author":"H Ding","year":"2012","unstructured":"Ding H, Zhou D, Hao S, Zhou L, He W, Nie J, Hou FF, Liu Y. Sonic Hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol. 2012;23(5):801\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"7796_CR102","doi-asserted-by":"publisher","first-page":"F770","DOI":"10.1152\/ajprenal.00232.2015","volume":"309","author":"AA Rauhauser","year":"2015","unstructured":"Rauhauser AA, Ren C, Lu D, Li B, Zhu J, McEnery K, Vadnagara K, Zepeda-Orozco D, Zhou XJ, Lin F, Jetten AM, Attanasio M. Hedgehog signaling indirectly affects tubular cell survival after obstructive kidney injury. Am J Physiol Ren Physiol. 2015;309(9):F770\u20138.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"4","key":"7796_CR103","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.ajpath.2011.12.039","volume":"180","author":"SL Fabian","year":"2012","unstructured":"Fabian SL, Penchev RR, St-Jacques B, Rao AN, Sipil\u00e4 P, West KA, McMahon AP, Humphreys BD. Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol. 2012;180(4):1441\u201353.","journal-title":"Am J Pathol"},{"issue":"5","key":"7796_CR104","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3892\/ijmm.2016.2546","volume":"37","author":"Y Bai","year":"2016","unstructured":"Bai Y, Lu H, Lin C, Xu Y, Hu D, Liang Y, Hong W, Chen B. Sonic hedgehog-mediated epithelial-mesenchymal transition in renal tubulointerstitial fibrosis. Int J Mol Med. 2016;37(5):1317\u201327.","journal-title":"Int J Mol Med"},{"key":"7796_CR105","doi-asserted-by":"publisher","first-page":"1018298","DOI":"10.3389\/fmed.2022.1018298","volume":"9","author":"D Wang","year":"2023","unstructured":"Wang D, Yin L, Chen R, Tan W, Liang L, Xiang J, Zhang H, Zhou X, Deng H, Guo B, Wang Y. Senescent renal tubular epithelial cells activate fibroblasts by secreting Shh to promote the progression of diabetic kidney disease. Front Med (Lausanne). 2023;9:1018298.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"7796_CR106","doi-asserted-by":"publisher","first-page":"e134796","DOI":"10.1172\/jci.insight.134796","volume":"5","author":"T Josefs","year":"2020","unstructured":"Josefs T, Barrett TJ, Brown EJ, Quezada A, Wu X, Voisin M, Amengual J, Fisher EA. Neutrophil extracellular traps promote macrophage inflammation and impair atherosclerosis resolution in diabetic mice. JCI Insight. 2020;5(7):e134796.","journal-title":"JCI Insight"},{"issue":"6","key":"7796_CR107","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41419-018-0538-5","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L, Zhao Y, Lai D, Zhang P, Yang Y, Li Y, Fei K, Jiang G, Fan J. Neutrophil extracellular traps promote macrophage pyroptosis in sepsis. Cell Death Dis. 2018;9(6):597.","journal-title":"Cell Death Dis"},{"issue":"6245","key":"7796_CR108","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1126\/science.aaa8064","volume":"349","author":"A Warnatsch","year":"2015","unstructured":"Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science. 2015;349(6245):316\u201320.","journal-title":"Science"},{"issue":"8","key":"7796_CR109","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41419-022-05138-4","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li Y, Chen Z, Yuan Y, Su Q, Ye K, Chen C, Li G, Song Y, Chen H, Xu Y. GSDMD-dependent neutrophil extracellular traps promote macrophage-to-myofibroblast transition and renal fibrosis in obstructive nephropathy. Cell Death Dis. 2022;13(8):693.","journal-title":"Cell Death Dis"},{"key":"7796_CR110","doi-asserted-by":"crossref","unstructured":"Jia H, Yue G, Li P, Peng R, Jin R, Chen Y, Cao H, Yang K, Zhang X, Yi X, Wu Y, Deng X, Chen X, Ma L, Zhao Y, Zhou X, Tao T, Shen X, Zhang X, Tao Y, Zhou H. Neutrophil extracellular traps license macrophage production of chemokines to facilitate CD8\u2009+\u2009T cell infiltration in obstruction-induced renal fibrosis. Protein Cell 2025 Feb 25:pwaf020.","DOI":"10.1093\/procel\/pwaf020"},{"issue":"12","key":"7796_CR111","doi-asserted-by":"publisher","first-page":"e156876","DOI":"10.1172\/JCI156876","volume":"132","author":"S Ryu","year":"2022","unstructured":"Ryu S, Shin JW, Kwon S, Lee J, Kim YC, Bae YS, Bae YS, Kim DK, Kim YS, Yang SH, Kim HY. Siglec-F-expressing neutrophils are essential for creating a profibrotic microenvironment in renal fibrosis. J Clin Invest. 2022;132(12):e156876.","journal-title":"J Clin Invest"},{"issue":"3","key":"7796_CR112","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41581-019-0110-2","volume":"15","author":"PM Tang","year":"2019","unstructured":"Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15(3):144\u201358.","journal-title":"Nat Rev Nephrol"},{"key":"7796_CR113","doi-asserted-by":"publisher","first-page":"117079","DOI":"10.1016\/j.biopha.2024.117079","volume":"177","author":"G Li","year":"2024","unstructured":"Li G, Yang H, Zhang D, Zhang Y, Liu B, Wang Y, Zhou H, Xu ZX, Wang Y. The role of macrophages in fibrosis of chronic kidney disease. Biomed Pharmacother. 2024;177:117079.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"7796_CR114","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/ki.2013.135","volume":"84","author":"J Lu","year":"2013","unstructured":"Lu J, Cao Q, Zheng D, Sun Y, Wang C, Yu X, Wang Y, Lee VW, Zheng G, Tan TK, Wang X, Alexander SI, Harris DC, Wang Y. Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. Kidney Int. 2013;84(4):745\u201355.","journal-title":"Kidney Int"},{"key":"7796_CR115","doi-asserted-by":"publisher","first-page":"1153300","DOI":"10.1155\/2022\/1153300","volume":"2022","author":"J Lu","year":"2022","unstructured":"Lu J, Lv S, Pang J, Qin T, Yang Y, Lu W, Li Z, Yang G, Zhang J. M2c macrophages protect mice from Adriamycin-Induced nephropathy by upregulating CD62L in Tregs. Mediators Inflamm. 2022;2022:1153300.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"7796_CR116","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.kint.2018.10.041","volume":"95","author":"T Chen","year":"2019","unstructured":"Chen T, Cao Q, Wang Y, Harris DCH. M2 macrophages in kidney disease: biology, therapies, and perspectives. Kidney Int. 2019;95(4):760\u201373.","journal-title":"Kidney Int"},{"issue":"34","key":"7796_CR117","doi-asserted-by":"publisher","first-page":"20741","DOI":"10.1073\/pnas.1917663117","volume":"117","author":"PM Tang","year":"2020","unstructured":"Tang PM, Zhang YY, Xiao J, Tang PC, Chung JY, Li J, Xue VW, Huang XR, Chong CC, Ng CF, Lee TL, To KF, Nikolic-Paterson DJ, Lan HY. Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage-myofibroblast transition. Proc Natl Acad Sci U S A. 2020;117(34):20741\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"7796_CR118","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1681\/ASN.2016050573","volume":"28","author":"YY Wang","year":"2017","unstructured":"Wang YY, Jiang H, Pan J, Huang XR, Wang YC, Huang HF, To KF, Nikolic-Paterson DJ, Lan HY, Chen JH. Macrophage-to-Myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft injury. J Am Soc Nephrol. 2017;28(7):2053\u201367.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"7796_CR119","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1681\/ASN.2020060806","volume":"31","author":"BR Conway","year":"2020","unstructured":"Conway BR, O\u2019Sullivan ED, Cairns C, O\u2019Sullivan J, Simpson DJ, Salzano A, Connor K, Ding P, Humphries D, Stewart K, Teenan O, Pius R, Henderson NC, B\u00e9n\u00e9zech C, Ramachandran P, Ferenbach D, Hughes J, Chandra T, Denby L. Kidney Single-Cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease. J Am Soc Nephrol. 2020;31(12):2833\u201354.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"7796_CR120","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41423-024-01190-6","volume":"21","author":"Q Ouyang","year":"2024","unstructured":"Ouyang Q, Wang C, Sang T, Tong Y, Zhang J, Chen Y, Wang X, Wu L, Wang X, Liu R, Chen P, Liu J, Shen W, Feng Z, Zhang L, Sun X, Cai G, Li LL, Chen X. Depleting profibrotic macrophages using bioactivated in vivo assembly peptides ameliorates kidney fibrosis. Cell Mol Immunol. 2024;21(8):826\u201341.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"7796_CR121","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1159\/000343283","volume":"36","author":"L Liu","year":"2012","unstructured":"Liu L, Kou P, Zeng Q, Pei G, Li Y, Liang H, Xu G, Chen S. CD4\u2009+\u2009T Lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis. Am J Nephrol. 2012;36(4):386\u201396.","journal-title":"Am J Nephrol"},{"issue":"4","key":"7796_CR122","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ki.2010.177","volume":"78","author":"TT Tapmeier","year":"2010","unstructured":"Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W. Pivotal role of CD4\u2009+\u2009T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010;78(4):351\u201362.","journal-title":"Kidney Int"},{"issue":"1","key":"7796_CR123","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/ndt\/gfy098","volume":"34","author":"BM Law","year":"2019","unstructured":"Law BM, Wilkinson R, Wang X, Kildey K, Lindner M, Beagley K, Healy H, Kassianos AJ. Effector \u03b3\u03b4 T cells in human renal fibrosis and chronic kidney disease. Nephrol Dial Transpl. 2019;34(1):40\u20138.","journal-title":"Nephrol Dial Transpl"},{"key":"7796_CR124","doi-asserted-by":"publisher","first-page":"109741","DOI":"10.1016\/j.biopha.2019.109741","volume":"123","author":"CH Weng","year":"2020","unstructured":"Weng CH, Li YJ, Wu HH, Liu SH, Hsu HH, Chen YC, Yang CW, Chu PH, Tian YC. Interleukin-17A induces renal fibrosis through the ERK and Smad signaling pathways. Biomed Pharmacother. 2020;123:109741.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"7796_CR125","doi-asserted-by":"publisher","first-page":"e130651","DOI":"10.1172\/jci.insight.130651","volume":"5","author":"F do Valle Duraes","year":"2020","unstructured":"do Valle Duraes F, Lafont A, Beibel M, Martin K, Darribat K, Cuttat R, Waldt A, Naumann U, Wieczorek G, Gaulis S, Pfister S, Mertz KD, Li J, Roma G, Warncke M. Immune cell landscaping reveals a protective role for regulatory T cells during kidney injury and fibrosis. JCI Insight. 2020;5(3):e130651.","journal-title":"JCI Insight"},{"issue":"6","key":"7796_CR126","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.amjms.2021.01.022","volume":"361","author":"J Song","year":"2021","unstructured":"Song J, Gong YH, Yan X, Liu Y, Zhang M, Luo J, Jiang CM, Zhang M, Shi GP, Zhu W. Regulatory T cells accelerate the repair process of renal fibrosis by regulating mononuclear macrophages. Am J Med Sci. 2021;361(6):776\u201385.","journal-title":"Am J Med Sci"},{"issue":"4","key":"7796_CR127","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.4049\/jimmunol.1501232","volume":"196","author":"Y Dong","year":"2016","unstructured":"Dong Y, Yang M, Zhang J, Peng X, Cheng J, Cui T, Du J. Depletion of CD8\u2009+\u2009T cells exacerbates CD4\u2009+\u2009T Cell-Induced Monocyte-to-Fibroblast transition in renal fibrosis. J Immunol. 2016;196(4):1874\u201381.","journal-title":"J Immunol"},{"issue":"1","key":"7796_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18010001","volume":"18","author":"H Wang","year":"2016","unstructured":"Wang H, Wang J, Bai Y, Li J, Li L, Dong Y. CD11c\u207a CD8\u207a T cells reduce renal fibrosis following ureteric obstruction by inducing fibroblast apoptosis. Int J Mol Sci. 2016;18(1):1.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"7796_CR129","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.bbagen.2019.05.020","volume":"1863","author":"W Diao","year":"2019","unstructured":"Diao W, Chen W, Cao W, Yuan H, Ji H, Wang T, Chen W, Zhu X, Zhou H, Guo H, Zhao X. Astaxanthin protects against renal fibrosis through inhibiting myofibroblast activation and promoting CD8+ T cell recruitment. Biochim Biophys Acta Gen Subj. 2019;1863(9):1360\u201370.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"7","key":"7796_CR130","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/biom11070990","volume":"11","author":"M Gao","year":"2021","unstructured":"Gao M, Wang J, Zang J, An Y, Dong Y. The mechanism of CD8+ T cells for reducing myofibroblasts accumulation during renal fibrosis. Biomolecules. 2021;11(7):990.","journal-title":"Biomolecules"},{"issue":"8","key":"7796_CR131","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.ymthe.2022.04.024","volume":"30","author":"L Li","year":"2022","unstructured":"Li L, Tang W, Zhang Y, Jia M, Wang L, Li Q, Han Q, Peng X, Xie Y, Wu J, Wang Z, Zhen J, Wang X, Liu M, Sun Y, Zhang C, Yi F. Targeting tissue-resident memory CD8+ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis. Mol Ther. 2022;30(8):2746\u201359.","journal-title":"Mol Ther"},{"key":"7796_CR132","doi-asserted-by":"publisher","first-page":"107877","DOI":"10.1016\/j.intimp.2021.107877","volume":"99","author":"T Zhang","year":"2021","unstructured":"Zhang T, Wang M, Zhang J, Feng X, Liu Z, Cheng Z. Association between tubulointerstitial CD8\u2009+\u2009T cells and renal prognosis in lupus nephritis. Int Immunopharmacol. 2021;99:107877.","journal-title":"Int Immunopharmacol"},{"key":"7796_CR133","doi-asserted-by":"publisher","first-page":"118487","DOI":"10.1016\/j.lfs.2020.118487","volume":"261","author":"L Yang","year":"2020","unstructured":"Yang L, Guo J, Yu N, Liu Y, Song H, Niu J, Gu Y. Tocilizumab Mimotope alleviates kidney injury and fibrosis by inhibiting IL-6 signaling and ferroptosis in UUO model. Life Sci. 2020;261:118487.","journal-title":"Life Sci"},{"issue":"4","key":"7796_CR134","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40620-023-01845-z","volume":"37","author":"C Seneschall","year":"2024","unstructured":"Seneschall C, Law S, Roufosse C, Woodham S, Kousios A. Tocilizumab (anti-IL-6) treatment for AA renal amyloidosis in a patient with advanced chronic kidney disease, a case report. J Nephrol. 2024;37(4):1147\u201352.","journal-title":"J Nephrol"},{"issue":"1","key":"7796_CR135","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5414\/CN109971","volume":"95","author":"M Fukuda","year":"2021","unstructured":"Fukuda M, Sawa N, Hoshino J, Ohashi K, Motoaki M, Ubara Y. Tocilizumab preserves renal function in rheumatoid arthritis with AA amyloidosis and end-stage kidney disease: two case reports. Clin Nephrol. 2021;95(1):54\u201361.","journal-title":"Clin Nephrol"},{"issue":"4","key":"7796_CR136","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1538\/expanim.22-0034","volume":"71","author":"KTO Erdem","year":"2022","unstructured":"Erdem KTO, Bedir Z, Kuyrukluyildiz U, Tas HG, Suleyman Z, Bulut S, Mendil AS, Sarigul C, Unver E, Suleyman H. Effect of Tocilizumab on ischemia-reperfusion-induced oxido-inflammatory renal damage and dysfunction in rats. Exp Anim. 2022;71(4):491\u20139.","journal-title":"Exp Anim"},{"issue":"8","key":"7796_CR137","doi-asserted-by":"publisher","first-page":"e28941","DOI":"10.1097\/MD.0000000000028941","volume":"101","author":"E Sugawara","year":"2022","unstructured":"Sugawara E, Sato T, Amasaki Y, Katsumata K. Successful treatment with Tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report. Med (Baltim). 2022;101(8):e28941.","journal-title":"Med (Baltim)"},{"issue":"8","key":"7796_CR138","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00210-019-01655-w","volume":"392","author":"AM Abdelrahman","year":"2019","unstructured":"Abdelrahman AM, Al Suleimani Y, Shalaby A, Ashique M, Manoj P, Ali BH. Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(8):1005\u201313.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"7796_CR139","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/ndt\/gfh127","volume":"19","author":"YM Chen","year":"2004","unstructured":"Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transpl. 2004;19(5):1106\u201315.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"7796_CR140","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1440-1797.2004.00267.x","volume":"9","author":"SL Lin","year":"2004","unstructured":"Lin SL, Chen YM, Chiang WC, Tsai TJ, Chen WY. Pentoxifylline: a potential therapy for chronic kidney disease. Nephrol (Carlton). 2004;9(4):198\u2013204.","journal-title":"Nephrol (Carlton)"},{"issue":"1","key":"7796_CR141","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000150600","volume":"29","author":"YY Ng","year":"2009","unstructured":"Ng YY, Chen YM, Tsai TJ, Lan XR, Yang WC, Lan HY. Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am J Nephrol. 2009;29(1):43\u201353.","journal-title":"Am J Nephrol"},{"issue":"9","key":"7796_CR142","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1681\/ASN.2005040435","volume":"16","author":"SL Lin","year":"2005","unstructured":"Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3\/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol. 2005;16(9):2702\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"7796_CR143","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pathophys.2018.08.004","volume":"25","author":"H Ma","year":"2018","unstructured":"Ma H, Lee S, Yang Y, Bedi P, Chou SY. Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction. Pathophysiology. 2018;25(4):419\u201325.","journal-title":"Pathophysiology"},{"issue":"12","key":"7796_CR144","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1097\/01.ASN.0000034909.10994.8A","volume":"13","author":"SL Lin","year":"2002","unstructured":"Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol. 2002;13(12):2916\u201329.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"7796_CR145","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1681\/ASN.2005010001","volume":"16","author":"JF Navarro","year":"2005","unstructured":"Navarro JF, Mora C, Muros M, Garc\u00eda J. Additive antiproteinuric effect of Pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16(7):2119\u201326.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"7796_CR146","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40261-013-0057-1","volume":"33","author":"S Badri","year":"2013","unstructured":"Badri S, Dashti-Khavidaki S, Ahmadi F, Mahdavi-Mazdeh M, Abbasi MR, Khalili H. Effect of add-on Pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial. Clin Drug Investig. 2013;33(3):215\u201322.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"7796_CR147","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1053\/j.ajkd.2008.11.026","volume":"53","author":"RM Perkins","year":"2009","unstructured":"Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of Pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53(4):606\u201316.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"7796_CR148","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1681\/ASN.2014010012","volume":"26","author":"JF Navarro-Gonz\u00e1lez","year":"2015","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C, Muros de Fuentes M, Chahin J, M\u00e9ndez ML, Gallego E, Mac\u00eda M, del Castillo N, Rivero A, Getino MA, Garc\u00eda P, Jarque A, Garc\u00eda J. Effect of Pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015;26(1):220\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"7796_CR149","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12882-025-04399-3","volume":"26","author":"ARM Galal","year":"2025","unstructured":"Galal ARM, Teama NM, Abu-Elfotuha K, Alatawi AD, Alshareef H, Hamdan AME, Aljabri A, Alshibani M, Zalat ZAM. The potential adding therapeutic effect of Pentoxifylline and\/or folic acid for chronic kidney disease patients: randomized controlled trial. BMC Nephrol. 2025;26(1):468.","journal-title":"BMC Nephrol"},{"issue":"2","key":"7796_CR150","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/0300060516663094","volume":"45","author":"D Liu","year":"2017","unstructured":"Liu D, Wang LN, Li HX, Huang P, Qu LB, Chen FY. Pentoxifylline plus ACEIs\/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis. J Int Med Res. 2017;45(2):383\u201398.","journal-title":"J Int Med Res"},{"issue":"12","key":"7796_CR151","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/antiox13121471","volume":"13","author":"JS Wang","year":"2024","unstructured":"Wang JS, Tsai PH, Tseng KF, Lin CL, Chen FY, Chang CT, Shen MY. Long-Term Pentoxifylline therapy is associated with a reduced risk of atherosclerotic cardiovascular disease by inhibiting oxidative stress and cell apoptosis in diabetic kidney disease patients. Antioxid (Basel). 2024;13(12):1471.","journal-title":"Antioxid (Basel)"},{"issue":"1","key":"7796_CR152","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12933-024-02393-x","volume":"23","author":"J Donate-Correa","year":"2024","unstructured":"Donate-Correa J, Ferri CM, Mora-Fern\u00e1ndez C, P\u00e9rez-Delgado N, Gonz\u00e1lez-Luis A, Navarro-Gonz\u00e1lez JF. Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial. Cardiovasc Diabetol. 2024;23(1):314.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"7796_CR153","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc18-0078","volume":"41","author":"JF Navarro-Gonz\u00e1lez","year":"2018","unstructured":"Navarro-Gonz\u00e1lez JF, S\u00e1nchez-Ni\u00f1o MD, Donate-Correa J, Mart\u00edn-N\u00fa\u00f1ez E, Ferri C, P\u00e9rez-Delgado N, G\u00f3rriz JL, Mart\u00ednez-Castelao A, Ortiz A, Mora-Fern\u00e1ndez C. Effects of Pentoxifylline on soluble Klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care. 2018;41(8):1817\u201320.","journal-title":"Diabetes Care"},{"issue":"5","key":"7796_CR154","doi-asserted-by":"publisher","first-page":"771","DOI":"10.34067\/KID.0000000000000425","volume":"5","author":"A Upadhyay","year":"2024","unstructured":"Upadhyay A. SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback. Kidney360. 2024;5(5):771\u201382.","journal-title":"Kidney360"},{"issue":"15","key":"7796_CR155","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde AM, Wheeler DC. DAPA-CKD trial committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"24","key":"7796_CR156","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. CREDENCE trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"2","key":"7796_CR157","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY The","year":"2023","unstructured":"The EMPA-KIDNEY, Collaborative G, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"7796_CR158","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sj\u00f6str\u00f6m CD, Stef\u00e1nsson BV, Langkilde AM, Wheeler DC, Heerspink HJL. DAPA-CKD trial committees and Investigators. Effects of Dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32(9):2352\u201361.","journal-title":"J Am Soc Nephrol"},{"issue":"4S","key":"7796_CR159","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"5","key":"7796_CR160","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 Inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587\u201397.","journal-title":"Circulation"},{"issue":"12","key":"7796_CR161","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/obr.12755","volume":"19","author":"PC Lee","year":"2018","unstructured":"Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19(12):1630\u201341.","journal-title":"Obes Rev"},{"issue":"3","key":"7796_CR162","first-page":"191","volume":"48","author":"Y Ishibashi","year":"2016","unstructured":"Ishibashi Y, Matsui T, Yamagishi S, Tofogliflozin. A highly selective inhibitor of SGLT2 blocks Proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016;48(3):191\u20135.","journal-title":"Horm Metab Res"},{"issue":"9","key":"7796_CR163","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","volume":"47","author":"A Ojima","year":"2015","unstructured":"Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of Sodium-Glucose cotransporter 2 exerts Anti-Inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-Receptor axis. Horm Metab Res. 2015;47(9):686\u201392.","journal-title":"Horm Metab Res"},{"issue":"18","key":"7796_CR164","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation Signaling\/Autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405.","journal-title":"Circulation"},{"key":"7796_CR165","doi-asserted-by":"publisher","first-page":"113947","DOI":"10.1016\/j.biopha.2022.113947","volume":"156","author":"YP Lu","year":"2022","unstructured":"Lu YP, Wu HW, Zhu T, Li XT, Zuo J, Hasan AA, Reichetzeder C, Delic D, Yard B, Klein T, Kr\u00e4mer BK, Zhang ZY, Wang XH, Yin LH, Dai Y, Zheng ZH, Hocher B. Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5\/6-nephrectomy. Biomed Pharmacother. 2022;156:113947.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"7796_CR166","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000505144","volume":"51","author":"G Castoldi","year":"2020","unstructured":"Castoldi G, Carletti R, Ippolito S, Colzani M, Barzaghi F, Stella A, Zerbini G, Perseghin G, di Gioia CRT. Renal Anti-Fibrotic effect of sodium glucose cotransporter 2 Inhibition in angiotensin II-Dependent hypertension. Am J Nephrol. 2020;51(2):119\u201329.","journal-title":"Am J Nephrol"},{"key":"7796_CR167","doi-asserted-by":"publisher","first-page":"112606","DOI":"10.1016\/j.biopha.2021.112606","volume":"146","author":"S Zeng","year":"2022","unstructured":"Zeng S, Delic D, Chu C, Xiong Y, Luo T, Chen X, Gaballa MMS, Xue Y, Chen X, Cao Y, Hasan AA, Stadermann K, Frankenreiter S, Yin L, Kr\u00e4mer BK, Klein T, Hocher B. Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor Blockade with Telmisartan in 5\/6 nephrectomised rats on high salt diet. Biomed Pharmacother. 2022;146:112606.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"7796_CR168","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","volume":"94","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524\u201335.","journal-title":"Kidney Int"},{"key":"7796_CR169","doi-asserted-by":"publisher","first-page":"121671","DOI":"10.1016\/j.lfs.2023.121671","volume":"322","author":"L Feng","year":"2023","unstructured":"Feng L, Chen Y, Li N, Yang X, Zhou L, Li H, Wang T, Xie M, Liu H. Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP\/TAZ activation. Life Sci. 2023;322:121671.","journal-title":"Life Sci"},{"issue":"1","key":"7796_CR170","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00018-025-05688-8","volume":"82","author":"X Cai","year":"2025","unstructured":"Cai X, Cao H, Wang M, Yu P, Liang X, Liang H, Xu F, Cai M. SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2. Cell Mol Life Sci. 2025;82(1):159.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"7796_CR171","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3390\/cells10061457","volume":"10","author":"J Xu","year":"2021","unstructured":"Xu J, Kitada M, Ogura Y, Liu H, Koya D. Dapagliflozin restores impaired autophagy and suppresses inflammation in high Glucose-Treated HK-2 cells. Cells. 2021;10(6):1457.","journal-title":"Cells"},{"issue":"8","key":"7796_CR172","doi-asserted-by":"publisher","first-page":"101690","DOI":"10.1016\/j.xcrm.2024.101690","volume":"5","author":"H Hu","year":"2024","unstructured":"Hu H, Li W, Hao Y, Peng Z, Zou Z, Wei J, Zhou Y, Liang W, Cao Y. The SGLT2 inhibitor Dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy. Cell Rep Med. 2024;5(8):101690.","journal-title":"Cell Rep Med"},{"issue":"3","key":"7796_CR173","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","volume":"21","author":"JD Smeijer","year":"2025","unstructured":"Smeijer JD, Kohan DE, Dhaun N, Noronha IL, Liew A, Heerspink HJL. Endothelin receptor antagonists in chronic kidney disease. Nat Rev Nephrol. 2025;21(3):175\u201388.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"7796_CR174","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/ASN.2013080830","volume":"25","author":"D de Zeeuw","year":"2014","unstructured":"de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH. The endothelin antagonist Atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25(5):1083\u201393.","journal-title":"J Am Soc Nephrol"},{"issue":"10184","key":"7796_CR175","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D. SONAR committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937\u201347.","journal-title":"Lancet"},{"issue":"10388","key":"7796_CR176","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V. PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584\u201394.","journal-title":"Lancet"},{"issue":"6","key":"7796_CR177","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J. ALIGN study Investigators. Atrasentan in patients with IgA nephropathy. N Engl J Med. 2025;392(6):544\u201354.","journal-title":"N Engl J Med"},{"issue":"11","key":"7796_CR178","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1681\/ASN.2018010091","volume":"29","author":"H Trachtman","year":"2018","unstructured":"Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R. DUET study Group. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745\u201354.","journal-title":"J Am Soc Nephrol"},{"issue":"10417","key":"7796_CR179","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Ma\u0142ecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V. DUPRO steering committee and PROTECT Investigators. Efficacy and safety of sparsentan versus Irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390.","journal-title":"Lancet"},{"issue":"10416","key":"7796_CR180","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, Mercier AK, \u00c5strand M, Ueckert S, Greasley PJ, Ambery P. Zibotentan in combination with Dapagliflozin compared with Dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet. 2023;402(10416):2004\u201317.","journal-title":"Lancet"},{"issue":"10","key":"7796_CR181","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.0000000000000436","volume":"35","author":"JD Smeijer","year":"2024","unstructured":"Smeijer JD, Wasehuus VS, Dhaun N, G\u00f3rriz JL, Soler MJ, \u00c5strand M, Mercier AK, Greasley PJ, Ambery P, Heerspink HJL. Effects of Zibotentan alone and in combination with Dapagliflozin on fluid retention in patients with CKD. J Am Soc Nephrol. 2024;35(10):1381\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"7796_CR182","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1111\/dom.16468","volume":"27","author":"V Wasehuus","year":"2025","unstructured":"Wasehuus V, Smeijer JD, Ambery P, Greasley PJ, Wijkmark E, Wheeler DC, Rossing P, Heerspink HJL. Effects of combined treatment with Zibotentan and Dapagliflozin compared to Dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease. Diabetes Obes Metab. 2025;27(8):4311\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"7796_CR183","doi-asserted-by":"publisher","first-page":"e012","DOI":"10.1621\/nrs.05012","volume":"5","author":"S Viengchareun","year":"2007","unstructured":"Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lomb\u00e8s M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:e012.","journal-title":"Nucl Recept Signal"},{"issue":"1","key":"7796_CR184","doi-asserted-by":"publisher","first-page":"T83","DOI":"10.1530\/JOE-17-0155","volume":"234","author":"TJ Cole","year":"2017","unstructured":"Cole TJ, Young MJ. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: mineralocorticoid receptor null mice: informing cell-type-specific roles. J Endocrinol. 2017;234(1):T83\u201392.","journal-title":"J Endocrinol"},{"key":"7796_CR185","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fphar.2017.00313","volume":"8","author":"GH Tesch","year":"2017","unstructured":"Tesch GH, Young MJ. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front Pharmacol. 2017;8:313.","journal-title":"Front Pharmacol"},{"issue":"13","key":"7796_CR186","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/bph.15719","volume":"179","author":"D Clarisse","year":"2022","unstructured":"Clarisse D, Deng L, de Bosscher K, Lother A. Approaches towards tissue-selective Pharmacology of the mineralocorticoid receptor. Br J Pharmacol. 2022;179(13):3235\u201349.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"7796_CR187","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019;96(2):302\u201319.","journal-title":"Kidney Int"},{"issue":"3","key":"7796_CR188","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","volume":"42","author":"A Nishiyama","year":"2019","unstructured":"Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42(3):293\u2013300.","journal-title":"Hypertens Res"},{"key":"7796_CR189","doi-asserted-by":"crossref","unstructured":"Nakamura T, Girerd S, Jaisser F, Barrera-Chimal J. Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney Int Suppl (2011). 2022;12(1):12\u201318.","DOI":"10.1016\/j.kisu.2021.11.004"},{"issue":"1","key":"7796_CR190","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","volume":"12","author":"JM Luther","year":"2022","unstructured":"Luther JM, Fogo AB. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int Suppl (2011). 2022;12(1):63\u20138.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"2","key":"7796_CR191","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152\u201361.","journal-title":"Eur Heart J"},{"issue":"1","key":"7796_CR192","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340.","journal-title":"J Endocrinol"},{"issue":"31","key":"7796_CR193","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","volume":"43","author":"AK Pandey","year":"2022","unstructured":"Pandey AK, Bhatt DL, Cosentino F, Marx N, Rotstein O, Pitt B, Pandey A, Butler J, Verma S. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J. 2022;43(31):2931\u201345.","journal-title":"Eur Heart J"},{"issue":"4","key":"7796_CR194","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","volume":"31","author":"A Struthers","year":"2008","unstructured":"Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153\u20138.","journal-title":"Clin Cardiol"},{"issue":"24","key":"7796_CR195","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target trial emulation: A framework for causal inference from observational data. JAMA. 2022;328(24):2446\u20137.","journal-title":"JAMA"},{"issue":"1","key":"7796_CR196","doi-asserted-by":"publisher","first-page":"9641","DOI":"10.1038\/s41467-025-64640-3","volume":"16","author":"CA Wang","year":"2025","unstructured":"Wang CA, Lai HW, Chen JY, Wang WJ, Lin LC, Chiu YL, Cheng CY, Wu VC. Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation. Nat Commun. 2025;16(1):9641.","journal-title":"Nat Commun"},{"issue":"7","key":"7796_CR197","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000518254","volume":"52","author":"K Droebner","year":"2021","unstructured":"Droebner K, Pavkovic M, Grundmann M, Hartmann E, Goea L, Nordlohne J, Klar J, Eitner F, Kolkhof P. Direct blood Pressure-Independent Anti-Fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis. Am J Nephrol. 2021;52(7):588\u2013601.","journal-title":"Am J Nephrol"},{"issue":"6","key":"7796_CR198","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal J, Estrela GR, Lechner SM, Giraud S, El Moghrabi S, Kaaki S, Kolkhof P, Hauet T, Jaisser F. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018;93(6):1344\u201355.","journal-title":"Kidney Int"},{"key":"7796_CR199","doi-asserted-by":"publisher","first-page":"948658","DOI":"10.3389\/fimmu.2022.948658","volume":"13","author":"P Qiang","year":"2022","unstructured":"Qiang P, Hao J, Yang F, Han Y, Chang Y, Xian Y, Xiong Y, Gao X, Liang L, Shimosawa T, Xu Q. Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor\/TGF-\u03b21 pathway in mice induced with aldosterone. Front Immunol. 2022;13:948658.","journal-title":"Front Immunol"},{"issue":"5","key":"7796_CR200","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney Injury-Mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017;69(5):870\u20138.","journal-title":"Hypertension"},{"issue":"9","key":"7796_CR201","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM. Mineralocorticoid receptor antagonist tolerability study\u2013Diabetic nephropathy (ARTS-DN) study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA. 2015;314(9):884\u201394.","journal-title":"JAMA"},{"issue":"23","key":"7796_CR202","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"7796_CR203","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"12","key":"7796_CR204","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758\u201364.","journal-title":"Nat Med"},{"issue":"6","key":"7796_CR205","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL. FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"8","key":"7796_CR206","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, Droebner K, Joseph A, H\u00fcser J, Eitner F. Effects of finerenone combined with empagliflozin in a model of Hypertension-Induced End-Organ damage. Am J Nephrol. 2021;52(8):642\u201352.","journal-title":"Am J Nephrol"},{"issue":"6","key":"7796_CR207","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M. CONFIDENCE Investigators. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025;393(6):533\u201343.","journal-title":"N Engl J Med"},{"issue":"10","key":"7796_CR208","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1007\/s11255-025-04512-3","volume":"57","author":"Q Gao","year":"2025","unstructured":"Gao Q, Lin H, Zhao Z, Peng S, Wu Q, Dong X, Yin Y, Xu L, Ma J, Tao Y, Feng Z, Liu S, Wen F. Effectiveness and safety of finerenone in the treatment of IgA nephrology patients: a retrospective, real-world study. Int Urol Nephrol. 2025;57(10):3365\u201371.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"7796_CR209","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40620-025-02240-6","volume":"38","author":"C Tang","year":"2025","unstructured":"Tang C, Si FL, Chen P, Hou WY, Yang HY, Lv JC, Shi SF, Zhou XJ, Liu LJ, Zhang H. Effectiveness and safety of finerenone in non-diabetic patients with IgA nephropathy. J Nephrol. 2025;38(6):1691\u20133.","journal-title":"J Nephrol"},{"issue":"5","key":"7796_CR210","doi-asserted-by":"publisher","first-page":"sfaf125","DOI":"10.1093\/ckj\/sfaf125","volume":"18","author":"QR Wang","year":"2025","unstructured":"Wang QR, Wu L, Huang J, Pan H, Wang XF, Li L, Han F, Wang YF, Wu ML, Yang Y. Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study. Clin Kidney J. 2025;18(5):sfaf125.","journal-title":"Clin Kidney J"},{"key":"7796_CR211","doi-asserted-by":"crossref","unstructured":"Ostrominski JW, Filippatos G, Claggett BL, Miao ZM, Desai AS, Jhund PS, Henderson A, Rohwedder K, Brinker MD, Scalise A, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2025 Sep 12.","DOI":"10.1681\/ASN.0000000823"},{"issue":"1","key":"7796_CR212","doi-asserted-by":"publisher","first-page":"2545939","DOI":"10.1080\/0886022X.2025.2545939","volume":"47","author":"F Li","year":"2025","unstructured":"Li F, Han J, Zhang W, Lv J, Wang Z, Li H, Jin L, Feng J, Lu W, Sun J. Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD. Ren Fail. 2025;47(1):2545939.","journal-title":"Ren Fail"},{"issue":"4","key":"7796_CR213","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.TP.0000151721.99418.48","volume":"79","author":"FS Shihab","year":"2005","unstructured":"Shihab FS, Bennett WM, Yi H, Andoh TF. Effect of Pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation. 2005;79(4):419\u201326.","journal-title":"Transplantation"},{"key":"7796_CR214","doi-asserted-by":"publisher","first-page":"174503","DOI":"10.1016\/j.ejphar.2021.174503","volume":"911","author":"X Bai","year":"2021","unstructured":"Bai X, Nie P, Lou Y, Zhu Y, Jiang S, Li B, Luo P. Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence. Eur J Pharmacol. 2021;911:174503.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"7796_CR215","doi-asserted-by":"publisher","first-page":"e83593","DOI":"10.1371\/journal.pone.0083593","volume":"8","author":"JF Chen","year":"2013","unstructured":"Chen JF, Liu H, Ni HF, Lv LL, Zhang MH, Zhang AH, Tang RN, Chen PS, Liu BC. Improved mitochondrial function underlies the protective effect of Pirfenidone against tubulointerstitial fibrosis in 5\/6 nephrectomized rats. PLoS ONE. 2013;8(12):e83593.","journal-title":"PLoS ONE"},{"key":"7796_CR216","doi-asserted-by":"publisher","first-page":"116666","DOI":"10.1016\/j.lfs.2019.116666","volume":"233","author":"ZZ Qiu","year":"2019","unstructured":"Qiu ZZ, He JM, Zhang HX, Yu ZH, Zhang ZW, Zhou H. Renoprotective effects of Pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model. Life Sci. 2019;233:116666.","journal-title":"Life Sci"},{"issue":"6","key":"7796_CR217","doi-asserted-by":"publisher","first-page":"F676","DOI":"10.1152\/ajprenal.00507.2012","volume":"304","author":"JF Chen","year":"2013","unstructured":"Chen JF, Ni HF, Pan MM, Liu H, Xu M, Zhang MH, Liu BC. Pirfenidone inhibits macrophage infiltration in 5\/6 nephrectomized rats. Am J Physiol Ren Physiol. 2013;304(6):F676\u201385.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"6","key":"7796_CR218","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2220\/biomedres.34.309","volume":"34","author":"X Ji","year":"2013","unstructured":"Ji X, Naito Y, Weng H, Ma X, Endo K, Kito N, Yanagawa N, Yu Y, Li J, Iwai N. Renoprotective mechanisms of Pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways. Biomed Res. 2013;34(6):309\u201319.","journal-title":"Biomed Res"},{"issue":"8","key":"7796_CR219","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/nep.12831","volume":"22","author":"Z Li","year":"2017","unstructured":"Li Z, Liu X, Wang B, Nie Y, Wen J, Wang Q, Gu C. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis. Nephrol (Carlton). 2017;22(8):589\u201397.","journal-title":"Nephrol (Carlton)"},{"issue":"5","key":"7796_CR220","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2215\/CJN.01050207","volume":"2","author":"ME Cho","year":"2007","unstructured":"Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2(5):906\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"7796_CR221","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22(6):1144\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"7796_CR222","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1042\/CS20170134","volume":"131","author":"F Liu","year":"2017","unstructured":"Liu F, Wang L, Qi H, Wang J, Wang Y, Jiang W, Xu L, Liu N, Zhuang S. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease. Clin Sci (Lond). 2017;131(16):2125\u201343.","journal-title":"Clin Sci (Lond)"},{"issue":"10","key":"7796_CR223","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41419-021-04248-9","volume":"12","author":"A Jamadar","year":"2021","unstructured":"Jamadar A, Suma SM, Mathew S, Fields TA, Wallace DP, Calvet JP, Rao R. The tyrosine-kinase inhibitor nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death Dis. 2021;12(10):947.","journal-title":"Cell Death Dis"},{"issue":"9","key":"7796_CR224","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3390\/ph17091147","volume":"17","author":"M Maggisano","year":"2024","unstructured":"Maggisano M, Mondini L, Chernovsky M, Confalonieri P, Salton F, Reccardini N, Kodric M, Geri P, Confalonieri M, Hughes M, Cifaldi R, Ruaro B. Safety of nintedanib in a patient with chronic pulmonary fibrosis and kidney disease. Pharmaceuticals (Basel). 2024;17(9):1147.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"7796_CR225","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13256-017-1384-2","volume":"11","author":"I Ismail","year":"2017","unstructured":"Ismail I, Nigam S, Parnham A, Srinivasa V. Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report. J Med Case Rep. 2017;11(1):214.","journal-title":"J Med Case Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07796-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:03:54Z","timestamp":1773227034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07796-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":225,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7796"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07796-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}